Oxford Immunotec Global PLC (NASDAQ:OXFD) shares shot up 5.4% on Monday . The company traded as high as $10.07 and last traded at $9.80, with a volume of 93,424 shares changing hands. The stock had previously closed at $9.30.

A number of research firms have recently weighed in on OXFD. Zacks Investment Research upgraded Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a report on Thursday. BTIG Research reaffirmed a “buy” rating and set a $17.00 price target on shares of Oxford Immunotec Global PLC in a research report on Tuesday, August 2nd. Finally, Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Oxford Immunotec Global PLC in a research report on Sunday, June 26th.

The stock’s market capitalization is $218.92 million. The stock has a 50 day moving average price of $8.86 and a 200-day moving average price of $9.71.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last posted its earnings results on Tuesday, August 2nd. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. The firm had revenue of $19.20 million for the quarter, compared to analysts’ expectations of $18.10 million. During the same quarter last year, the company posted ($0.33) EPS. The firm’s revenue was up 34.3% on a year-over-year basis. On average, analysts predict that Oxford Immunotec Global PLC will post ($1.29) EPS for the current fiscal year.

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.